3,415 research outputs found
Possible Fulde-ferrell-larkin-ovchinnikov Inhomogeneous Superconducting State In Cecoin5
No full textWe report specific heat and thermal conductivity measurements of the heavy fermion superconductor CeCoIn5 in the vicinity of the superconducting critical field Hc2, with magnetic field in the plane of this quasi-2D compound and at temperatures down to 50 mK. The superconducting phase transition changes from second to first order for field above 10 T, as evident from a sharp peak in specific heat and a jump in thermal conductivity, indicating the importance of the Pauli limiting effect in CeCoIn5. In the same range of magnetic field, we observe a second specific heat anomaly within the superconducting state. We interpret this anomaly as a signature of a Fulde-Ferrell-Larkin-Ovchinnikov (FFLO) inhomogeneous superconducting state. In addition, the thermal conductivity data as a function of field display a kink at a field Hk below the superconducting critical field, which closely coincides with the low-temperature anomaly in specific heat, tentatively identified with the appearance of the FFLO superconducting state. Our results indicate that the thermal conductivity is enhanced within the FFLO state, and call for further theoretical investigations of the real-space structure of the order parameter (and in particular, the structure of vortices) and of the thermal transport within the inhomogeneous FFLO state. © 2005 Elsevier B.V. All rights reserved.359-361SPEC. ISS.416423Fulde, P., Ferrell, R.A., (1964) Phys. Rev., 135, pp. A550Larkin, A.I., Ovchinnikov, Y.N., (1964) J. Exptl. Theoret. Phys. USSR, 47, p. 1130Larkin, A.I., Ovchinnikov, Y.N., (1965) Sov. Phys. JETP, 20, p. 762Clogston, A.M., (1962) Phys. Rev. Lett., 2, p. 9Gruenberg, L.W., Gunther, L., (1966) Phys. Rev. Lett., 16, p. 996Maki, K., (1966) Phys. Rev., 148, p. 362Gloos, K., (1993) Phys. Rev. Lett., 70, p. 501Huxley, A., (1993) J. Phys.: Condens. Matter, 5, p. 7709Tenya, K., (1999) Physica B, 259-261, p. 692Norman, M.R., (1993) Phys. Rev. Lett., 71, p. 3391Movshovich, R., (2001) Phys. Rev. Lett., 86, p. 5152Bianchi, A., (2002) Phys. Rev. Lett., 89, p. 137002Maki, K., Tsuneto, T., (1964) Progr. Theoret. Phys., 31, p. 945Tayama, T., (2002) Phys. Rev. B, 65, p. 180504Hall, D., (2001) Phys. Rev. B, 64, p. 212508Shimahara, H., (1994) Phys. Rev. B, 50, p. 12760Murphy, T.P., (2002) Phys. Rev. B, 65, p. 100514Izawa, K., (2001) Phys. Rev. Lett., 87, p. 057002Tachiki, M., (1996) Z. Phys. B, 100, p. 369Houzet, M., Buzdin, A., (2001) Phys. Rev. B, 63, p. 184521Agterberg, D.F., Yang, K., (2001) J. Phys.: Condens. Matter, 13, p. 9259Bulaevskii, L.N., Guseinov, A.A., (1976) Sov. J. Low Temp. Phys., 2, p. 140Adachi, H., Koikegami, S., Ikeda, R., (2003) J. Phys. Soc. Japan, 72, p. 2460C. Martin, et al., cond-mat/0309125Watanabe, T., Kasahara, Y., Izawa, K., Sakakibara, T., Van Der Beek, C.J., Hanaguri, T., Shishido, H., Matsuda, Y., (2004) Phys. Rev. B, 70, p. 020506Buzdin, A.I., private communicationMaki, K., (1967) Phys. Rev., 158, p. 397Petrovic, C., (2001) J. Phys.: Condens. Matter, 13, pp. L337Bianchi, A., (2003) Phys. Rev. Lett., 91, p. 187004Won, H., Maki, K., Haas, S., Oeschler, N., Weickert, F., Gegenwart, P., (2004) Phys. Rev. B, 69, p. 180504H.A. Radovan, R.J. Zieve, J.S. Kim, G.R. Stewart, cond-mat/0306451Zuo, F., (2000) Phys. Rev. B, 61, p. 750Radovan, H.A., (2003) Nature, 425, p. 51R. Combescot, C. Mora, cond-mat/0311042Vekhter, I., private communicationBoulaevskii, L., private communicationKlein, U., (2000) J. Low Temp. Phys., 118, p. 9
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
No full textOxygen as a control on seafloor biological communities and their roles in sedimentary carbon cycling
No full text13C tracer experiments were conducted at sites spanning the steep oxygen, organic matter, and biological
community gradients across the Arabian Sea oxygen minimum zone, in order to quantify the role that benthic
fauna play in the short-term processing of organic matter (OM) and to determine how this varies among different
environments. Metazoan macrofauna and macrofauna-sized foraminiferans took up as much as 56 6 13 mg of
added C m22 (685 mg C m22 added) over 2–5 d, and at some sites this uptake was similar in magnitude to
bacterial uptake and/or total respiration. Bottom-water dissolved oxygen concentrations exerted a strong control
over metazoan macrofaunal OM processing. At oxygen concentrations .7 mmol L21 (0.16 ml L21), metazoan
macrofauna were able to take advantage of abundant OM and to dominate OM uptake, while OM processing at
O2 concentrations of 5.0 mmol L21 (0.11 ml L21) was dominated instead by (macrofaunal) foraminiferans. This
led us to propose the hypothesis that oxygen controls the relative dominance of metazoan macrofauna and
foraminifera in a threshold manner, with the threshold lying between 5 and 7 mmol L21 (0.11 to 0.16 ml L21).
Large metazoan macrofaunal biomass and high natural concentrations of OM were also associated with rapid
processing of fresh OM by the benthic community. Where they were present, the polychaete Linopherus sp. and
the calcareous foraminiferan Uvigerina ex gr. semiornata, dominated the uptake of OM above and below,
respectively, the proposed threshold concentrations of bottom-water oxygen
A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK)
No full textBACKGROUND: Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.PATIENTS AND METHODS: Patients with disease progression after ?1 VEGF targeted therapy were eligible to participate in this double-blind, randomised (1:1) phase II study. The study compared the combination cediranib 30mg once daily (OD) and saracatinib 175mg OD (CS) (n=69) or cediranib 45mg OD and placebo OD (C) (n=69). Archived tissue was used for biomarker analysis (SRC, FAK, VHL, PTB1b and HIF2?: n=86).The primary endpoint was progression free survival (PFS) by RECIST v1.1.RESULTS: Between 2010 and 2012, 138 patients were randomised across 16 UK sites. The characteristics of the two groups were well balanced. Partial responses were seen in 13.0% for C and 14.5% for CS respectively (P>0.05). There was no significant difference in PFS [5.4 months (3.6-7.3 months) for C and 3.9 (2.4-5.3 months) for CS; Hazard Ratio (HR) 1.18 (0.94-1.48)], or overall survival (OS) [14.2 months (11.2-16.8 months) for C and 10.0 (6.7-13.2 months) for CS; [HR 1.28 (1.00-1.63)]. There was no significant difference in the frequency of key adverse events, dose reductions or drug discontinuations. None of the biomarkers were prognostic for PFS or OS. Focal adhesion kinase (FAK) overexpression correlated with an OS benefit [HR 2.29 (1.09-4.82) p>0.05], but not PFS, for CS.CONCLUSIONS: Saracatinib did not increase the efficacy of a VEGF targeted therapy (cediranib) in this setting. Biomarker analysis did not identify consistent predictive biomarkers.<br/
Veterinary Clinical Pathology. An integrated undergraduate course
No full textAt completion of this course, veterinary students should be able to:
• Provide examples of ways in which laboratory tests are used in the diagnosis, prognosis, and monitoring of disease; in monitoring health; in evaluating stress; and in evaluating nutritional status, exercise, or training.
• List the basic haematological and biochemical tests used in the evaluation of animal health and diagnosis of disease in domestic animals.
• Use appropriate units and terminology for laboratory tests and laboratory test abnormalities
• List the variables responsible for preanalytical, analytical and postanalytical sources of error in laboratory test results and describe ways of avoiding them.
• List the factors affecting reference intervals that must be considered in their calculation and use.
• Plan and equip an in-practice laboratory, including basic instruments, supplies, stains, and reagents.
• Interpret laboratory test results using appropriate reference intervals and with consideration of available clinical information. As part of this process:
o Make a list of both quantitative and qualitative abnormalities in test results.
o Relate abnormal test values to each other when possible, and to clinical findings.
o Construct a list of differential diagnoses to explain the laboratory abnormalities.
o Propose additional potentially useful tests for confirming or ruling out potential diseases or pathophysiologic processes
Upper critical field in the organic superconductor β″ - (H2 CF2 SO3: Possibility of Fulde-Ferrell-Larkin-Ovchinnikov state
No full textWe report upper critical-field measurements in the metal-free-all-organic superconductor β″ - (ET) 2 SF5 CH2 CF2 SO3 obtained from measuring the in-plane penetration depth using the tunnel diode oscillator technique. For magnetic field applied parallel to the conducting planes the low-temperature upper critical fields are found to exceed the Pauli limiting field calculated by using a semiempirical method. Furthermore, we found a signature that could be the phase transition between the superconducting vortex state and the Fulde-Ferrell-Larkin-Ovchinnikov state in the form of a kink just below the upper critical field and only at temperatures below 1.23 K. © 2009 The American Physical Society
Trapped Between Modernism and Postmodernism: A Critical Study of Philip Larkin's Poetry
No full textNot availabl
Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA
No full textRecent success in phase I/II clinical trials (Konstan, M. W.; Davis, P. B.; Wagener, J. S.; Hilliard, K. A.; Stern, R. C.; Milgram, L. J.; Kowalczyk, T. H.; Hyatt, S. L.; Fink, T. L.; Gedeon, C. R.; Oette, S. M.; Payne, J. M.; Muhammad, O.; Ziady, A. G.; Moen, R. C.; Cooper, M. J. Hum. Gene Ther. 2004, 15 (12), 1255-69) has highlighted pegylated poly-L-lysine (C1K30-PEG) as a nonviral gene delivery agent capable of achieving clinically significant gene transfer levels in vivo. This study investigates the potential of a C1K30-PEG gene delivery system for cancer gene therapy and evaluates its mode of cellular entry with the purpose of developing an optimally formulated prototype for tumor cell transfection. C1K30-PEG complexes have a neutral charge and form rod-like and toroid-like nanoparticles. Comparison of the transfection efficiency achieved by C1K30-PEG with other cationic lipid and polymeric vectors demonstrates that C1K30-PEG transfects cells more efficiently than unpegylated poly-L-lysine and compares well to commercially available vectors. In vivo gene delivery by C1K30-PEG nanoparticles to a growing subcutaneous murine tumor was also demonstrated. To determine potential barriers to C1K30-PEG gene delivery, the entry mechanism and intracellular fate of rhodamine labeled complexes were investigated. Using cellular markers to delineate the pathway taken by the complexes upon cellular entry, only minor colocalization was observed with EEA-1, a marker of early endosomes. No colocalization was observed between the complexes and the transferrin receptor, which is a marker for clathrin-coated pits. In addition, complexes were not observed to enter late endosomes/lysosomes. Cellular entry of the complexes was completely inhibited by the macropinocytosis inhibitor, amiloride, indicating that the complexes enter cells via macropinosomes. Such mechanistic studies are an essential step to support future rational design of pegylated poly-L-lysine vectors to improve the efficiency of gene delivery.PUBM: Print; JID: 101197791; 0 (Polyethylene Glycols); 25104-18-1 (Polylysine); 9007-49-2 (DNA); ppublishSource type: Electronic(1
A BIOECONOMIC ANALYSIS OF MANAGEMENT ALTERNATIVES FOR THE U.S. NORTH ATLANTIC SWORDFISH FISHERY
No full textA bioeconomic model of the North Atlantic swordfish (Xiphias gladius) fishery is developed to evaluate policy-relevant management options as changes from the status quo. The model accounts for heterogeneity in vessel and trip characteristics, including the number of sets placed and catch composition. Results indicate that five-year economic returns to the U.S. Atlantic pelagic longline (PLL) fleet can be increased by reducing juvenile swordfish mortality or fleet size (and possibly changing fleet composition). These policies may not be effective, however, if implemented simultaneously. Domestic management of the swordfish fishery was found to be effective, despite the small share of the international quota. Lastly, producer surpluses earned by the domestic PLL vessel owners are significantly affected by: (1) changes in swordfish demand (due to, for example, the recent chef's boycott), (2) success at negotiating the swordfish quota share, (3) catch rates, and (4) relative costs of heterogeneous vessels and trip behavior.Resource /Energy Economics and Policy,
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/ K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
No full textBackground: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after 36-month follow-up for all living patients.
Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo. The primary endpoint was PFS; secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics.
Results: Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive
dabrafenib plus trametinib (n = 211) or dabrafenib monotherapy (n = 212). At data cut-off (15 February 2016), outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively. Twenty-five patients receiving monotherapy crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat principle). Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib. Three-year OS with the combination reached 62% in the most favourable
subgroup (normal lactate dehydrogenase and <3 organ sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase). The dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety signals were detected with long-term use.
Conclusions: These data demonstrate that durable (3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting
- …
